Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma (PETEY)

O

OSI Pharmaceuticals

Status and phase

Terminated
Phase 2

Conditions

Recurrent or Refractory Pediatric Ependymoma

Treatments

Drug: etoposide
Drug: erlotinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT01032070
OSI-774-205
2009-016836-11 (EudraCT Number)

Details and patient eligibility

About

This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.

Full description

This is a phase 2 study involving a 1:1 randomization of 40 patients with recurrent or refractory pediatric ependymoma who will receive either erlotinib or oral etoposide.

Enrollment

25 patients

Sex

All

Ages

1 to 21 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Recurrent of refractory ependymoma or subependymoma
  • Performance Status (PS): Lansky ≥ 50% for patients ≤ 10 years of age or Karnofsky ≥ 50% for patients >10 years of age
  • Measurable disease, defined as 1 measurable lesion that can be accurately measured in 2 planes that has not received radiation therapy within 12 weeks
  • Recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
  • ≥ 1 year to ≤ 21 years
  • Serum creatinine for patients ≤ 5 years in age is ≤ 0.8 mg/dL or Creatinine Clearance/Glomerular Filtration Rate (GFR) ≥ 70 mL/min/m^2
  • Serum creatinine for patients > 5 and ≤ 10 years in age is ≤ 1.0 mg/dL or Creatinine Clearance/GFR ≥ 70 mL/min/m^2
  • Serum creatinine for patients > 10 and ≤ 15 years in age is ≤ 1.2 mg/dL or Creatinine Clearance/GFR ≥ 70 mL/min/m^2
  • Serum creatinine for patients > 15 years in age is ≤ 1.5 mg/dL or Creatinine Clearance/GFR ≥ 70 mL/min/m^2
  • Total bilirubin is ≤ 1.5 x upper limit of normal for age
  • Alanine aminotransferase (ALT) ≤ 3 x upper limit of normal
  • Absolute neutrophil count > 1000/µL
  • Platelet count > 100,000/µL
  • Hemoglobin > 8 gm/dL
  • Neurologically stable for at least 7 days prior to randomization
  • If receiving corticosteroids, patients must be on a stable or decreasing dose for at least 7 days before randomization
  • Patients of reproductive potential must agree to proactive effective contraceptive measures for the duration of the study and for at least 90 days after completion of study drug

Exclusion criteria

  • Previously received epidermal growth factor receptor (EGFR)-targeted therapy
  • Previously received oral etoposide
  • Received craniospinal radiotherapy within 24 weeks prior to randomization
  • Received field radiotherapy to the target lesion within 12 weeks prior to randomization
  • Received symptomatic metastatic disease within 14 days prior to randomization
  • Received myelosuppressive chemotherapy within 21 days before randomization
  • Received growth factors within 7 days prior to randomization
  • Participating in another investigational drug trial
  • Received a biologic agent within 7 days prior to randomization
  • Received a monoclonal antibody within 28 days prior to randomization
  • Taking cytochrome P450 (CYP)3A4 or CYP1A2 inhibitors/inducers within 14 days prior to randomization
  • Taking proton pump inhibitors within 14 days prior to randomization
  • Smoking during treatment
  • Pregnant or breast-feeding females

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

25 participants in 2 patient groups

Erlotinib
Experimental group
Description:
Erlotinib was administered orally at a dose of 85 mg/m^2 per day continuously until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
Treatment:
Drug: erlotinib
Etoposide
Active Comparator group
Description:
Etoposide 50 mg/m^2 per day was administered orally for 21 days followed by a 7-day rest period until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
Treatment:
Drug: etoposide

Trial contacts and locations

28

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems